Find My Journal

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, Yohann Loriot, Nicholas J. Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta Retz, Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwénaëlle Gravis, Syed A. Hussain, Toshimi Takano, Ning Leng, Edward E. Kadel, Romain Banchereau, Priti S. Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Alain Ravaud

The Lancet, 2017

St Bartholomew's Hospital, Queen Mary University of London, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Hospital Universitario Virgen del Rocío, The Netherlands Cancer Institute, Université Paris-Saclay, Institut Gustave Roussy, Comprehensive Cancer Centers of Nevada, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Hôpital Européen Georges-Pompidou, Université Paris Cité, Klinikum rechts der Isar, Centro de Investigación Biomédica en Red de Cáncer, Alexandra Hospital, National and Kapodistrian University of Athens, Centre Léon Bérard, Institut Paoli-Calmettes, University Hospitals Plymouth NHS Trust, Toranomon Hospital, Bordeaux Population Health

View Free PDF Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

1404

Citations

View on Google Scholar